表紙
市場調査レポート

転移性結腸直腸癌:パイプライン分析

Metastatic Colorectal Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251592
出版日 ページ情報 英文 718 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
転移性結腸直腸癌:パイプライン分析 Metastatic Colorectal Cancer - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 718 Pages
概要

転移性結腸直腸癌は、体の他の部分まで広がる癌です。結腸癌、または直腸癌が広がると、多くの場合肝臓まで広がります。肺、骨または他の器官まで広がることもあります。 最も一般的な症侯は腹痛で、特にガス痛、激しい腹痛、あるいは膨満感があり、血便あるいは真っ黒な便が出ます。 治療には化学療法、手術、生物学的治療、放射線療法などの選択肢があります。

当レポートでは、転移性結腸直腸癌の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • 転移性結腸直腸癌 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7985IDB

Summary

Global Markets Direct's, 'Metastatic Colorectal Cancer - Pipeline Review, H1 2016', provides an overview of the Metastatic Colorectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Colorectal Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer
  • The report reviews pipeline therapeutics for Metastatic Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Colorectal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Colorectal Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Metastatic Colorectal Cancer Overview
  • Therapeutics Development
  • Metastatic Colorectal Cancer - Therapeutics under Development by Companies
  • Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Colorectal Cancer - Pipeline Products Glance
  • Metastatic Colorectal Cancer - Products under Development by Companies
  • Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development
  • Metastatic Colorectal Cancer - Therapeutics Assessment
  • Drug Profiles
  • Metastatic Colorectal Cancer - Recent Pipeline Updates
  • Metastatic Colorectal Cancer - Dormant Projects
  • Metastatic Colorectal Cancer - Discontinued Products
  • Metastatic Colorectal Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Metastatic Colorectal Cancer, H1 2016
  • Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by AB Science SA, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by AbbVie Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Alchemia Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Amgen Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Apexigen, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by ArQule, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Array BioPharma Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Baxalta Incorporated, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Bayer AG, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Biocon Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Bionomics Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Bionovis SA, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Celgene Corporation, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Celltrion, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Cipla Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by EirGenix Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by EnGeneIC Ltd, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Etubics Corporation, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Gilead Sciences, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Hemispherx Biopharma, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Hetero Drugs Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Ignyta, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Immatics Biotechnologies GmbH, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Immunomedics, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Mabion SA, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Mabtech Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by mAbxience S.A., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by MacroGenics, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by MedImmune, LLC, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Merck & Co., Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Merus B.V., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Mologen AG, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Morphotek, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Mycenax Biotech Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Natco Pharma Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Nektar Therapeutics, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Novartis AG, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by OBI Pharma, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Oncobiologics, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Panacea Biotec Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Pfizer Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Pharma Mar, S.A., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Pharmacyclics, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Precision Biologics, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Symphogen A/S, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Tocagen Inc., H1 2016
  • Metastatic Colorectal Cancer - Pipeline by Vaximm AG, H1 2016
  • Metastatic Colorectal Cancer - Pipeline by XBiotech USA, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Metastatic Colorectal Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Metastatic Colorectal Cancer - Dormant Projects, H1 2016
  • Metastatic Colorectal Cancer - Dormant Projects (Contd..1), H1 2016
  • Metastatic Colorectal Cancer - Dormant Projects (Contd..2), H1 2016
  • Metastatic Colorectal Cancer - Dormant Projects (Contd..3), H1 2016
  • Metastatic Colorectal Cancer - Dormant Projects (Contd..4), H1 2016
  • Metastatic Colorectal Cancer - Dormant Projects (Contd..5), H1 2016
  • Metastatic Colorectal Cancer - Dormant Projects (Contd..6), H1 2016
  • Metastatic Colorectal Cancer - Dormant Projects (Contd..7), H1 2016
  • Metastatic Colorectal Cancer - Dormant Projects (Contd..8), H1 2016
  • Metastatic Colorectal Cancer - Discontinued Products, H1 2016
  • Metastatic Colorectal Cancer - Discontinued Products (Contd..1), H1 2016
  • Metastatic Colorectal Cancer - Discontinued Products (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for Metastatic Colorectal Cancer, H1 2016
  • Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top